Valuation: Avicanna Inc.

Market Cap 15.84M 11.1M 9.92M 9.22M 8.39M 1.08B 15.91M 111M 43.38M 548M 41.69M 40.78M 1.76B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 15.56M 10.9M 9.74M 9.06M 8.25M 1.06B 15.63M 109M 42.61M 538M 40.95M 40.06M 1.73B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.71%
Yield 2024 *
-
Yield 2025 -
1 day+5.95%
1 week+7.51%
Current month-1.29%
1 month-8.50%
3 months-20.33%
6 months-34.53%
Current year-52.87%
1 week 0.06
Extreme 0.0596
0.08
1 month 0.06
Extreme 0.0596
0.09
Current year 0.06
Extreme 0.0596
0.18
1 year 0.06
Extreme 0.0596
0.22
3 years 0.06
Extreme 0.0596
0.53
5 years 0.06
Extreme 0.0596
0.72
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 30/04/2015
Chief Executive Officer 39 25/11/2016
Director of Finance/CFO - 14/09/2025
Director TitleAgeSince
Chairman 39 25/11/2016
Director/Board Member - 21/10/2018
Director/Board Member - 31/12/2025
Change 5-day change 1-year change 3-year change Capi.($)
+5.95%+7.51% - - 11.1M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +1.34%-2.66%+49.62%+110.98% 41.84B
Weighted average by Cap. +0.56%-2.94%+51.35%+115.57%

Financials

2024 2025
Net sales 25.46M 17.84M 15.95M 14.83M 13.49M 1.73B 25.57M 178M 69.73M 881M 67.02M 65.56M 2.83B 25.48M 17.86M 15.96M 14.84M 13.5M 1.73B 25.59M 178M 69.79M 882M 67.07M 65.61M 2.83B
Net income -3.62M -2.54M -2.27M -2.11M -1.92M -246M -3.63M -25.34M -9.91M -125M -9.52M -9.32M -402M -2.76M -1.93M -1.73M -1.61M -1.46M -187M -2.77M -19.33M -7.56M -95.49M -7.26M -7.11M -306M
Net Debt -339K -237K -212K -197K -180K -23M -340K -2.37M -928K -11.73M -892K -872K -37.6M -281K -197K -176K -163K -149K -19.05M -282K -1.97M -769K -9.71M -739K -723K -31.15M
Projected Income Statement - Annual - Avicanna Inc.
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
09/10/26 US$0.0764 +5.95% 114,100
08/10/26 US$0.0722 +0.72% 100
07/10/26 US$0.0716 +6.92% 100
06/10/26 US$0.0670 -4.49% 125,600
05/10/26 US$0.0702 -1.28% 300